Upstream Bio Launches With $200M Series A
Jun 3, 2022
The funding will allow Upstream to advance the company's lead program UPB-101, a clinical-stage monoclonal antibody targeting the TSLP receptor, and build a pipeline of assets to address immune-mediated diseases. The Series A round was led jointly by OrbiMed and Maruho Co., Ltd. with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital, and Altshuler Shaham Provident Funds Ltd.
At Upstream Bio we strive to reach the source of inflammation and conquer it. Their lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. Upstream Bio is leveraging diverse roots and the team's substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.